Thursday , October 17 2019
Home / venezuela / Insomnia, the possible causal disease of the coronary artery

Insomnia, the possible causal disease of the coronary artery

An international research team led by researchers at the University of Massachusetts Medical School in Moscow, Exeter, United Kingdom, has identified 57 genetic regions associated with insomnia symptoms. His report, which also indicates the causal link between insomnia and coronary artery disease, "Nature Genetics & # 39; It is published online edition.

"Our discoveries have confirmed that the function of genetics has been to find insomnia symptoms and four genetic diseases previously," says Jacqueline M. Lane, Genomic Medical Center and General Secretary's Office. Anesthesia, chemotherapy and critical pain. "They understand all of these identified areas, why some people find insomnia, paths and systems, and find new therapeutic goals," he added.

Insomnia affects 10 to 20 percent of the population and twins and family members inherit a third of the insomnia risk. Although evidence suggests that insomnia increases anxiety disorders, alcohol disorders, major depression and cardiometabolic disease, few are known about mechanisms.

Lane and Richa Saxena, MGH Genomics and Anesthesia Center, targeted by Nature Genetics & # 39; In 2017, more than 112,500 participants from the UK Biobank participated in the symptom of insomnia. For the current study, the group's analysis analyzed data from more than 450,000 participants in the British Biobank; 29% of them frequently reported symptoms of insomnia.

57 were examined sites of genes with autoimmune insomnia, not linked to known risk factors, such as lifestyle, caffeine consumption, depression or ultimate stress. Identified genomic regions are: genes involved in ubiquitin mediation in proteolytic – a process labeled to destroy proteins and appear in the brain, bone muscles and adrenal glands.

Although some of these genes link insomnia symptoms, legs that stop syndrome and coronary artery disease, the identified regions do not include neurotransmission genes involved in sleep regulation.

In order to verify whether the results of the BioBank in the UK are general to other populations, the authors have examined the HUNT study, the Norwegian epidemiological study and the Biosphere Biobank (United States). The 15,000 participants of the HUNT examinations reported a total of 47,600 controls and 4700 controls and 2,200 members. Biodiversity clinical diagnoses were attended by 14,240 checks, which confirmed the discovery of British biobanks.

New possible therapeutic targets

The subtitles used data detection devices for eight-day acceleration units in the United Kingdom, insomnia-related gene regions reduced sleep efficacy (sleep quality measure). sleep) and the duration of sleep, and the daily variations of sleep duration. The shared genetic factors associated with insensitive and naïve syndrome recognize the previous work of the MGH group and may lead to the insomnia of some patients with uncomfortable illnesses that are not recommended.

An analysis technique called Mendelen ausentziak, that is, one of the two characteristics of one person can create an insomnia symptoms due to the coronary artery disease, the symptoms of depression and a reduced sense of well-being. "Insomnia has had a huge impact on millions of people around the world. We know that there is no insomnia and chronic illness. Our findings now suggest that depression and heart disease are the result of persistent survival," says Samuel Jones, co-author of Exeter University.

The researcher at the MGH Lane adds: "All of these identified areas can create new therapeutic purposes for insomnia, 16 of them have known drug targets, and new causes of affliction indicate the availability of possible treatment of insomnia by coronary artery disease and depression."

The CEO of Exeter University Michael Weedon says: "There are problems with current treatments including insomnia, accessibility problems, addictions, and side effects. We will expand the understanding of underlying processes under insomnia for more personalized and better treatment. at the same time, reduce the number of people who suffer from insomnia and improve long-term health. "

Source link